Editor’s note: this article was published in the Aug. 1, 2024 issue of Pharmaceutical Technology Europe®
News|Articles|August 1, 2024
- Pharmaceutical Technology, August 2024
- Volume 48
- Issue 8
Separation and Purification Columns
Author(s)Pharmaceutical Technology Editors
These columns offer fast run times, optimal separation efficiency, and reliable results.
Advertisement
The Thermo Scientific SurePac Bio 550 SEC MDi columns enable fast separations of adeno-associated virus (AAV) monomers and aggregates. The columns are designed with 3 µm monodisperse particles and inert (MDi) column hardware aimed at providing superior AAV monomer retention and higher resolution of aggregates in cell and gene therapies.
These columns offer fast run times, optimal separation efficiency, and reliable results with the goal of accelerating time-to-market for novel therapeutics. In addition, Thermo’s DNAPac RP HPLC columns (pictured here) are offered in semi-preparative formats to enable scalability in the development of DNA/RNA oligonucleotides. The DNAPac RP semi-preparative columns are designed so that laboratories can navigate the expanding field of oligonucleotide therapies and precision medicine. The DNAPac RP semi-preparative column utilizes unique chemistry for enhanced performance across wide ranges of pH, temperature, and mobile-phase compositions, offering precise separations and sample purification.
Articles in this issue
about 2 years ago
Integrating Strategies for Formulation Successabout 2 years ago
Automating Development of Small-Molecule APIsabout 2 years ago
Considerations for Finished Product Inspection Systemsabout 2 years ago
Germany Amends and Approves the New Medical Research Actabout 2 years ago
Contracting Out Frees Sponsors Upabout 2 years ago
Frontrunners in Automated Cell and Gene Therapy Manufacturingabout 2 years ago
Igniting Pharma’s Potential?about 2 years ago
Demanding ImpartialityAdvertisement
Related to this article
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement